Blood‐based biomarkers of Alzheimer's disease: Standardization and comprehensiveness
Abstract Population aging is sweeping across the globe, resulting in a striking prevalence of Alzheimer's disease (AD) and dementia and a heavy economic burden. Given the time window of 10–20 years from pathological initiation to clinically detected cognitive impairment, early detection can sig...
Saved in:
Main Authors: | Ying Liu, Yu Guo, Jintai Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-12-01
|
Series: | Neuroprotection |
Subjects: | |
Online Access: | https://doi.org/10.1002/nep3.58 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of Alzheimer's Disease Blood Biomarkers With Sarcopenia Incidence and Progression: A 12‐Year Population‐Based Study
by: Chiara Ceolin, et al.
Published: (2025-06-01) -
Biomarkers and therapeutic targets in early Alzheimer’s disease: an Olink proteomics study
by: Jianan Wei, et al.
Published: (2025-07-01) -
Scouting Biomarkers for Alzheimer’s Disease via Network Analysis of Exosome Proteomics Data
by: Alexis Sagonas, et al.
Published: (2025-04-01) -
The impact of estimated cardiorespiratory fitness on Alzheimer's disease biomarkers and their relationships with cognitive decline
by: Adam J Paulsen, et al.
Published: (2025-04-01) -
New Possibilities for Evaluating Markers of Alzheimer's Disease in Blood Serum
by: S. V. Vorobev, et al.
Published: (2025-06-01)